Core Insights - Dassault Systèmes reported a fiscal year 2025 revenue of €6.24 billion ($7.44 billion), reflecting a 4% year-over-year growth at constant exchange rates [1] - Recurring revenue increased by 6%, driven primarily by an 11% growth in subscription services as more customers transitioned to cloud services [1] - The fourth quarter revenue grew only 1% at constant exchange rates, reaching €1.68 billion, which is at the lower end of the performance guidance range [1] Revenue Breakdown - The 3DEXPERIENCE platform and cloud services saw annual revenue growth of 10% and 8% respectively, largely driven by large contracts [1] - The life sciences segment, which includes Medidata clinical trial business, experienced a 2% decline in annual revenue due to pharmaceutical companies reducing new project initiations [1] - The industrial innovation software business grew by 6%, remaining the core growth engine for the company [1] Outlook for 2026 - The company projects a revenue growth of 3% to 5% at constant exchange rates for 2026 [1] - Operating margin is expected to be between 32.2% and 32.6% [1] - Earnings per share are forecasted to be between €1.30 and €1.34 [1]

Group 1 - GE Healthcare Technologies (GEHC) will acquire Intelerad Medical Systems Inc. for $2.3 billion in cash to expand its presence in cloud software and artificial intelligence [1] - Following the announcement, GE Healthcare's stock price remained relatively unchanged, with a year-to-date decline of 4.4% [1] - The medical imaging industry is undergoing transformation as companies leverage AI to assist in interpreting scan images, with Intelerad's software being significant in radiology and cardiology [1] Group 2 - Intelerad is expected to generate approximately $270 million in revenue in its first full fiscal year post-acquisition, contributing to robust growth in GE Healthcare's total revenue and adjusted EBIT [2] - The acquisition is the largest since GE Healthcare's spin-off from General Electric in 2023, with Intelerad being a private company founded in 1999 and operating in the U.S. and Canada [2] - Funding for the transaction will come from existing cash and debt financing, with completion expected in the first half of 2026 [2] Group 3 - Evercore serves as the financial advisor for GE Healthcare, while UBS Investment Bank acts as the financial advisor for Intelerad [3]